The Motley Fool
12 Jul 2026, 18:11 UTC · 2h ago
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
12 Jul 2026, 18:11 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
UroGen Pharma's first quarter revenue grew 152% to $51 million, driven by the launch of its bladder cancer therapy, Zusduri. — Triple-digit revenue growth and a successful product launch are primary catalysts for valuation increases in biotech.
+0.80The FDA cleared UroGen's investigational new drug application for UGN-501, with a Phase 1 study planned for the fourth quarter. — FDA clearance for a new drug candidate expands the company's pipeline and creates a future valuation catalyst.
+0.50Chief Medical Officer Mark Schoenberg sold 10,000 shares of URGN valued at $400,000 on July 9, 2026. — While insider selling can be a red flag, this was a pre-planned 10b5-1 trade and the executive retains a significant stake.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is showing strong growth momentum, significant revenue jumps from a successful drug launch, and a cleared FDA application.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
